Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies - Oakes, Tina M.; Kovacs, Richard; Rosen, Noah; Doty, Erin; Kemmer, Phebe; Aurora, Sheena K.; Camporeale, Angelo (Headache, 2020)
Keywords: Adult; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Blood pressure; Blood Pressure - drug effects; Calcitonin; Calcitonin Gene-Related Peptide - drug effects; calcitonin gene‐related peptide; Cardiovascular Diseases - chemically induced; cardiovascular risks; Chronic Disease; Confidence intervals; Covariance; Double-blind studies; Drug therapy; Echocardiography; EKG; Electrocardiography; Electrocardiography - drug effects; Embolism; Embolisms; Female; galcanezumab; Headache; Health risks; Heart attacks; Heart Rate - drug effects; Humans; hypertension; Ischemia; Male; Microvasculature; Middle Aged; Migraine; Migraine Disorders - prevention & control; Monoclonal antibodies; Myocardial infarction; Patients; Randomization; Thromboembolism; Thrombosis; Transient ischemic attack; Treatment Outcome; calcitonin gene-related peptide; cardiovascular risks; migraine; hypertension; galcanezumab; ischemia